Lung cancer trials in China

In China 1143 Also abroad 2747

1,143 trials · From ClinicalTrials.gov, checked 13 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
Assessment of Adebelizumab Combined With Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
Where
Beijing
Age
18 years and over
People
60
Run by
Peking University Cancer Hospital & Institute
See details and how to joinNCT06768307
Phase 1Taking people
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
Where
Beijing, Changsha, Guangzhou, Jinan, Jining, Shanghai, Shenyang, Shijiazhuang
Age
18 years and over
People
738 worldwide
Run by
NextCure, Inc.
See details and how to joinNCT06792552
No phaseTaking people
Acupoint Application for Chemotherapy-Induced Nausea and Vomiting in Lung Cancer
Where
Chongqing
Age
18 years to 75 years
People
60
Run by
Xiu Huang
See details and how to joinNCT07768124
Phase 3Taking people
To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy
Where
Suzhou
Age
18 years to 75 years
People
318
Run by
Allist Pharmaceuticals, Inc.
See details and how to joinNCT04853342
Phase 1/2Taking people
A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1
Where
Beijing, Changchun, Changsha, Chongqing, Hangzhou, Harbin, Hohhot, Hubei, Nanning, Shenyang, Shenzhen, Shijiazhuang, Xiamen, Xi’an, Zhengzhou
Age
18 years and over
People
104
Run by
Allist Pharmaceuticals, Inc.
See details and how to joinNCT05276726
Phase 1/2Taking people
Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
Where
Beijing, Changsha, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Linyi, Shanghai, Shenyang, Shenzhen, Wuhan, Xiamen, Zhengzhou
Age
18 years and over
People
240
Run by
Allist Pharmaceuticals, Inc.
See details and how to joinNCT05288205
Phase 3Taking people
JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
Where
Beijing, Cangzhou, Changsha, Chengdu, Fuzhou, Guangzhou, Haerbin, Hangzhou, Hefei, Jilin City, Jinan, Linyi, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Taiyuan, Taizhou, Tianjin, Wuhan, Wuxi, Xi’an, Zhengzhou
Age
18 years and over
People
392
Run by
Allist Pharmaceuticals, Inc.
See details and how to joinNCT06416410
Phase 1Taking people
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AST2303 Tablets (ABK3376 Tablets) in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Where
Shanghai
Age
18 years and over
People
120
Run by
Allist Pharmaceuticals, Inc.
See details and how to joinNCT06955988
Phase 3Taking people
Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
Where
Beijing, Shandong
Age
18 years and over
People
300
Run by
Allist Pharmaceuticals, Inc.
See details and how to joinNCT06956001
Phase 3Taking people
A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases
Where
Guangdong
Age
18 years and over
People
380
Run by
Allist Pharmaceuticals, Inc.
See details and how to joinNCT06970639
Phase 3Taking people
Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer
Where
Changsha
Age
18 years to 75 years
People
186
Run by
Hunan Province Tumor Hospital
See details and how to joinNCT07251582
No phaseTaking people
Real-World Outcomes of Resected EGFR-Mutated NSCLC Patients Treated With Adjuvant EGFR-TKI in China
Where
Beijing, Chengdu, Fuzhou, Guangzhou, Nanchang, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi'an, Xuzhou, Zhengzhou
Age
18 years and over
People
2,000
Run by
AstraZeneca
See details and how to joinNCT07593248
No phaseTaking people
Phase II Trial of Consolidative Thoracic Radiotherapy for ES-SCLC After Standard Care of Chemo-immunotherapy
Where
Shanghai
Age
18 years to 80 years
People
104
Run by
Ruijin Hospital
See details and how to joinNCT05552846
Phase 2Taking people
SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer
Where
Jilin City, Shanghai
Age
18 years to 75 years
People
206
Run by
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
See details and how to joinNCT07697586
Phase 2Taking people
NK Cells Plus ICI for SCLC Maintenance
Where
Tianjin
Age
18 years and over
People
42
Run by
Tianjin First Central Hospital
See details and how to joinNCT07759856
No phaseTaking people
Acupressure for Cough in Lung Cancer Survivors
Where
Shenzhen
Age
18 years and over
People
80 worldwide
Run by
The University of Hong Kong
See details and how to joinNCT07315672
Phase 1/2Taking people
AMT-116 in Combination With AK112 in Patients With Lung Cancer
Where
Guangzhou, Hangzhou
Age
18 years to 75 years
People
118
Run by
Multitude Therapeutics Inc.
See details and how to joinNCT07590531
Phase 3Taking people
A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation
Where
Shanghai
Age
18 years and over
People
300
Run by
Genfleet Therapeutics (Shanghai) Inc.
See details and how to joinNCT07668752
Phase 4Taking people
Oral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment for Older Adults With NSCLC
Where
Guangzhou, Hangzhou, Lishui, Shanghai, Suqian
Age
70 years and over
People
78
Run by
Shanghai Pulmonary Hospital, Shanghai, China
See details and how to joinNCT07754812
No phaseTaking people
ctDNA-driven Adaptive Proton Craniospinal Irradiation in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis After Resistance to Third-Generation TKIs in the Consolidation Phase
Where
Hefei, Nanjing
Age
18 years to 75 years
People
84
Run by
Shuanghu Yuan
See details and how to joinNCT07751536
No phaseNot yet taking people in China
Microbiota in Neoadjuvant Chemoimmunotherapy for NSCLC
Where
Guangzhou
Age
18 years to 80 years
People
100
Run by
Guangdong Provincial People's Hospital
See details and how to joinNCT07752589
Phase 3Taking people
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Where
Beijing, Changchun, Changsha, Chengdu, Chongqing, Haerbin, Hangzhou, Jiangxi, Jinan, Linyi, Neijiang, Shandong, Shanghai, Shenyang, Tianjin, Ürümqi, Wuhan, Xi'an, Xiangyang, Zhengzhou
Age
18 years and over
People
540 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06203210 · EU 2023-509628-16-00
No phaseTaking people
Analgesic Effects of Retro-superior Costotransverse Ligament Space Block for Video-assisted Thoracoscopic Surgery
Where
Nanjing
Age
18 years to 80 years
People
130
Run by
Nanjing First Hospital, Nanjing Medical University
See details and how to joinNCT07745881
Phase 2Not yet taking people in China
Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLC
Where
Guangzhou
Age
18 years and over
People
153
Run by
Guangdong Association of Clinical Trials
See details and how to joinNCT07750704
Phase 1Taking people
A Phase Ib Study of GC101 in NSCLC
Where
Shanghai
Age
18 years to 70 years
People
20
Run by
Shanghai Juncell Therapeutics
See details and how to joinNCT06473961